Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00997438 · ClinicalTrials.gov registry record · Phase 1
Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis
A Phase 1 study, sponsored by Portland VA Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
NCT00997438 is a Phase 1 study that has completed, run by Portland VA Medical Center. The registered enrollment target is 69 participants.
The verdict
NCT00997438, a Phase 1 study, has completed, sponsored by Portland VA Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
Study Summary
The purpose of this study is to learn about how the antioxidant, lipoic acid, works in the body and how it may help in the management of relapsing remitting and secondary progressive multiple sclerosis. This study will compare how subject's and healthy volunteers bodies absorb and break down the supplement. This information may help in developing new therapies.
Interventions
- DIETARY_SUPPLEMENT Lipoic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2010-08 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00997438
The ClinicalTrials.gov registry entry for NCT00997438 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Portland VA Medical Center, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lipoic Acid is the first listed.
NCT00997438 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00997438 about?
NCT00997438 is a clinical study titled "Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis". The purpose of this study is to learn about how the antioxidant, lipoic acid, works in the body and how it may help in the management of relapsing remitting and secondary progressive multiple sclerosis. This study will compare how subject's and healthy volunteers bodies absorb and break down the sup...
What is the current status of trial NCT00997438?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2010-08. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00997438?
The interventions under investigation include: Lipoic Acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00997438?
This trial is sponsored by Portland VA Medical Center, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.